ID   UKF-Rhb-1
AC   CVCL_4Z17
DR   Wikidata; Q54990406
RX   PubMed=19147553;
RX   PubMed=22170099;
RX   PubMed=23665679;
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 29-06-23; Version: 8
//
RX   PubMed=19147553; DOI=10.1158/0008-5472.CAN-08-1856;
RA   Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K.,
RA   Fehse B., Kammerer B., Doerr H.-W., Cinatl J. Jr.;
RT   "Reversal of P-glycoprotein-mediated multidrug resistance by the
RT   murine double minute 2 antagonist nutlin-3.";
RL   Cancer Res. 69:416-421(2009).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//